We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+1.82%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.41B
AUM Growth
-$960M
Cap. Flow
-$340M
Cap. Flow %
-5.3%
Top 10 Hldgs %
70.89%
Holding
50
New
7
Increased
8
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
2
GPCR icon
Structure Therapeutics
GPCR
+$32.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$29.7M
4
AKRO
Akero Therapeutics
AKRO
+$25.9M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$23.9M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$317M
2
ARGX icon
argenx
ARGX
+$129M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$102M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
NUVL
Nuvalent
NUVL
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$810M 12.63%
7,000,000
– –
UTHR icon
2
United Therapeutics
UTHR
$25.9B
$644M 10.05%
2,852,500
-57,499
-2% -$13.2M
ARGX icon
3
argenx
ARGX
$55.2B
$492M 7.67%
1,000,000
-263,500
-21% -$129M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.62B
$488M 7.61%
4,025,000
-602,888
-13% -$68.1M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$423M 6.59%
11,111,111
– –
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
$373M 5.82%
1,759,606
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$344M 5.36%
3,670,000
+89,445
+2% +$8.37M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$341M 5.31%
3,850,000
-150,000
-4% -$13.3M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$333M 5.2%
27,400,000
– –
KRYS icon
10
Krystal Biotech
KRYS
$10.7B
$298M 4.64%
2,565,555
+4,744
+0.2% +$579K
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$290M 4.53%
6,666,666
+1,111,111
+20% +$39.7M
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.5B
$227M 3.54%
1,555,000
+39,849
+3% +$7.5M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.5B
$179M 2.79%
1,011,111
-93,889
-8% -$17.9M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.19B
$167M 2.61%
4,900,000
– –
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$154M 2.4%
10,300,000
– –
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.58B
$114M 1.78%
1,999,999
+274,999
+16% +$15.2M
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.43B
$81.8M 1.28%
11,550,000
-505,000
-4% -$3.63M
ROIV icon
18
Roivant Sciences
ROIV
$23.8B
$54.3M 0.85%
4,651,162
-1,155,000
-20% -$13.1M
KYMR icon
19
Kymera Therapeutics
KYMR
$8.7B
$53.6M 0.84%
3,855,000
– –
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.51B
$53.5M 0.83%
1,500,000
+750,000
+100% +$29.7M
GPCR icon
21
Structure Therapeutics
GPCR
$3.38B
$50.4M 0.79%
+1,000,000
New +$32.2M
NUVL
22
DELISTED
Nuvalent
NUVL
$37.4M 0.58%
812,500
-787,500
-49% -$35M
MNKD icon
23
MannKind Corp
MNKD
$1.2B
$37.2M 0.58%
9,000,000
-100,000
-1% -$449K
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.69B
$37.1M 0.58%
2,555,555
-94,445
-4% -$1.79M
IOVA icon
25
Iovance Biotherapeutics
IOVA
$2.02B
$30.5M 0.48%
6,700,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Avoro Capital Advisors held 50 positions worth $6.41B, down 13% from $7.37B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Avoro Capital Advisors withdrew a net $340M in Q3 2023, closing 4 positions and reducing 12 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $317M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Structure Therapeutics worth $50.4M.

  • Avoro Capital Advisors's largest Q3 2023 buy was Structure Therapeutics: 1,000,000 shares worth $50.4M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $39.7M increase.
  • Avoro Capital Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $129M.
  • Avoro Capital Advisors fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $317M.
  • Avoro Capital Advisors's ten largest holdings make up 71% of its $6.41B portfolio in Q3 2023.
  • Avoro Capital Advisors opened 7 new positions and closed 4 in Q3 2023.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $6.41B.

Based on Avoro Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.